BrightPath Bio, Cellistic join forces to advance iPSC-derived CAR-NKT cell therapy for multiple myeloma

BrightPath Bio and Cellistic have entered into a collaboration aimed at advancing iPSC-derived CAR-NKT cell therapy. This partnership focuses on process development and clinical-scale manufacturing ... Read More